초록 ▼

Methods for preventing or for treating benzodiazepine site (BZD-S) associated syndromes comprising administering 2′ hydroxyflavone and flavone derivatives thereof which contain a hydroxyl group at the 2′ position to a patient in need thereof in an effective dose. Methods for extracting certain of th

Methods for preventing or for treating benzodiazepine site (BZD-S) associated syndromes comprising administering 2′ hydroxyflavone and flavone derivatives thereof which contain a hydroxyl group at the 2′ position to a patient in need thereof in an effective dose. Methods for extracting certain of the compounds from plant material are also described.

대표청구항 ▼

1. A method of preventing or treating a BZD-S associated syndrome in a patient in need thereof, comprising administering to the patient an effective non-toxic dose of a compound comprising: or a physiological salt thereof, wherein: R7is H or OH andR5, R6, R8, R3′, R4′, R5′ and R6′ are each, indep

1. A method of preventing or treating a BZD-S associated syndrome in a patient in need thereof, comprising administering to the patient an effective non-toxic dose of a compound comprising: or a physiological salt thereof, wherein: R7is H or OH andR5, R6, R8, R3′, R4′, R5′ and R6′ are each, independently, H, OH, a C1-C6alkyl, a C1-C6alkenyl or a C1-C6alkoxy; and wherein the syndrome is anxiety or convulsions.2. The method of claim 1, wherein R5is OH.3. The method of claim 1, wherein R6is OH.4. The method of claim 1, wherein R7is OH.5. The method of claim 1, wherein R5and R6are both OH.6. The method of claim 1, wherein R6and R7are both OH.7. The method of claim 1, wherein R5and R7are both OH.8. The method of claim 1, wherein the dose is administered in a single aliquot.9. The method of claim 1, wherein the dose is administered in two or more aliquots.10. A method of preventing or treating a BZD-S associated syndrome in a patient in need thereof, comprising administering to the patient an effective non-toxic dose of a compound comprising 5,7,2′-trihydroxy-6,8-dimethoxyflavone or a physiologically acceptable salt thereof; wherein the syndrome is anxiety or convulsions. 11. The method of claim 1, wherein R5, R6and R7are all OH.12. The method of claim 1, wherein R6is methoxy.13. The method of claim 1, wherein R8is methoxy.14. The method of claim 1, wherein R6and R8are both methoxy.15. A method of preventing or treating a BZD-S associated syndrome in a patient in need thereof, comprising administering to the patient an effective non-toxic dose of a compound comprising: or a physiological salt thereof, wherein: R7is H or OH andR1 5, R6, R8, R3′ and R4′ are each, independently, H, OH, a C1-C6alkyl, a C1-C6alkenyl or a C1-C6alkoxy; and wherein the syndrome is anxiety or convulsions.16. A pharmaceutical package comprising one or more containers filled with a compound comprising: or a physiological salt thereof, wherein: R7is H or OH andR5, R6, R8, R3′, R4′, R5′ and R6′ are each, independently, H, OH, a C1-C6alkyl, a C1-C6alkenyl or a C1-C6alkoxy.17. The package of claim 16 further comprising instructions for using the compound in the prevention or treatment of anxiety.18. The package of claim 16 further comprising instructions for using the compound in the prevention or treatment of convulsions.